Rising Healthcare Cost Containment And Delayed Approvals Will Erode Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 16 Analysts
Published
06 Aug 25
Updated
16 Aug 25
AnalystLowTarget's Fair Value
US$44.00
12.0% overvalued intrinsic discount16 Aug
US$49.30
1Y
41.2%7D
-1.0%1Y
41.2%7D
-1.0%